



May 31, 2016

## CareDx to Present at 2016 Jefferies Healthcare Conference

BRISBANE, Calif., May 31, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Peter Maag, CareDx President & Chief Executive Officer, and Charles Constanti, Chief Financial Officer, will be presenting and available for meetings at the 2016 Jefferies Healthcare Conference on June 8, 2016 at 4:30pm ET.

A live audio webcast of the presentation will be available online from the investor relations page of the Company's website at <http://investors.caredxinc.com>. The webcast replay of the presentation will begin approximately one hour after the conclusion of the live presentation and will be available on the Company's website for 90 days.

### About CareDx

CareDx, Inc., headquartered in Brisbane, California, is a global molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients. The Company markets AlloMap<sup>®</sup>, a gene expression test that aids clinicians in identifying heart transplant patients with stable graft function who have a low probability of moderate to severe acute cellular rejection. CareDx is pursuing the development of additional products for transplant monitoring using a variety of technologies, including AlloSure<sup>™</sup>, a next-generation sequencing-based test to detect donor-derived cell-free DNA after transplantation.

CareDx's, with its presence through Olerup AB, also develops, manufactures, markets and sells high quality products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs. Olerup SSP<sup>®</sup>, a set of HLA typing is used prior to hematopoietic stem cell/bone marrow transplantation and organ transplantation; and XM-ONE<sup>®</sup>, the first standardized test that quickly identifies a patient's antigens against HLA Class I, Class II or antibodies against a donor's endothelium. For more information, please visit: [www.CareDx.com](http://www.CareDx.com).

CareDx

### Media Contact

Molly Martell, CareDx, Inc.

T: +1 415-287-2397

### Investor Contact

Jamar Ismail, Westwicke Partners

T: 415-513-1282

 [Primary Logo](#)

Source: CareDx, Inc.

News Provided by Acquire Media